Understanding the Market | Chunli Medical rises over 9% again, overseas business has become an important source of income, and third-quarter performance has grown rapidly year-on-year
CHUNLI MEDICAL's stock price rose over 9% again, with a cumulative increase of nearly 25% after the earnings report. As of the time of writing, the stock price is HKD 20.44, with a trading volume of HKD 98.2915 million. The company's operating revenue for the first three quarters was RMB 756 million, a year-on-year increase of 48.75%; net profit was RMB 192 million, a year-on-year increase of 213.21%. The operating revenue for the third quarter was RMB 268 million, a year-on-year increase of 109.51%. Huatai Securities believes that overseas business has become an important source of revenue and expects it to continue to grow rapidly in the future, maintaining a "Buy" rating
According to Zhitong Finance APP, Chunli Medical (01858) has risen over 9% again, with a cumulative increase of nearly 25% after its earnings report. As of the time of writing, it is up 7.98%, priced at HKD 20.44, with a transaction volume of HKD 98.2915 million.
In terms of news, Chunli Medical recently released its performance report, showing an operating income of RMB 756 million in the first three quarters, a year-on-year increase of 48.75%; net profit of RMB 192 million, a year-on-year increase of 213.21%. The operating income for the third quarter was RMB 268 million, a year-on-year increase of 109.51%; net profit attributable to the parent company was RMB 77.0619 million, achieving a turnaround from loss to profit. Huatai Securities believes that the high-speed growth in the third quarter is mainly due to the company's steady advancement in international market development, continuous increase in export business revenue, and growth in sales of centralized procurement products, maintaining a "buy" rating for future overseas revenue growth.
The firm pointed out that the company is actively expanding its international market business, with rapid growth in overseas revenue, which has become an important source of income. The company's hip, knee, and spine product series have all successfully passed the CE annual system audit and supervision audit, and the knee prosthesis system has received FDA 510(K) approval in the United States, indicating that the company's technological advantages have reached an internationally leading level, providing strong international market competitiveness and laying a foundation for the continuous increase in the company's international sales. The ongoing expansion of overseas business is expected to maintain rapid growth in overseas performance in 2025
